Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb2513 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | XmAb2513 |
| Name | Type | Description |
|---|---|---|
| XmAb2513 | BIOLOGICAL | Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts. |
Inclusion Criteria: * Diagnosed with HL or ALCL. * Patients must have received two or more prior therapeutic regimens, one of which should include hematopoietic cell transplant, either autologous or allogeneic transplant. * If a hematopoietic cell transplant was refused, or the patient was not elig...
XmAb2513 is an investigational monoclonal antibody being studied for the treatment of Hodgkin Lymphoma. It was evaluated in a Phase 1 clinical trial that also included patients with Anaplastic Large Cell Lymphoma. The drug is not approved and remains in clinical development.
XmAb2513 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. Xencor is the sponsor of the clinical trial for this investigational monoclonal antibody.
XmAb2513 is in Phase 1 clinical development. A single Phase 1 trial has been completed, and the drug is not FDA approved. It remains an investigational agent under study for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
XmAb2513 has one completed clinical trial, registered as NCT00606645, titled 'Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma.' The Phase 1 study enrolled 23 participants in the United States and was not randomized or blinded.
XmAb2513 is not FDA approved. It is an investigational monoclonal antibody that has completed a Phase 1 clinical trial for Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma, but it has not received regulatory approval for any indication.